Sign Up to like & get
recommendations!
1
Published in 2020 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-020-02631-7
Abstract: Peptide vaccines represent an attractive alternative to conventional anti-tumor therapies, but have not yet achieved significant clinical efficacy with commonly used formulations. Combination of short antigenic peptides, synthetic melanin and TLR9 agonist (Toll-like receptor 9,…
read more here.
Keywords:
incomplete freund;
based vaccine;
melanin;
peptide vaccines ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-004709
Abstract: Water-in-oil emulsion incomplete Freund’s adjuvant (IFA) has been used as an adjuvant in preventive and therapeutic vaccines since its development. New generation, highly purified modulations of the adjuvant, Montanide incomplete seppic adjuvant (ISA)-51 and Montanide…
read more here.
Keywords:
cell;
cd4;
cancer peptide;
incomplete freund ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-019-0625-x
Abstract: BackgroundCancer vaccines require adjuvants to induce effective immune responses; however, there is no consensus on optimal adjuvants. We hypothesized that toll-like receptor (TLR)3 agonist polyICLC or TLR4 agonist lipopolysaccharide (LPS), combined with CD4 T cell…
read more here.
Keywords:
melanoma;
toll like;
incomplete freund;
cell responses ... See more keywords